Hi Thymus,
Thanks very much for posting the reference - I was wondering about potential competition myself.
My understanding from the reported research is that they are using siRNAs and they've discovered how to better protect them using nanopasrticles so they get to the target cells (more effectively than with present methods) where they switch off the particular gene slowing down the progress of healing cells getting to the wound.
I don't think we should underestimate the significance of this research. However, I don't feel it is a short term threat to TIS after all we have the runs on the board from a huigh quality human trial ( albeit not for the FDA). The next stage for the research appears to be trial on pigs so they still have a way to go.
The other point I'd make is that siRNA are not produced in the target cells by the body and have to be introduced - that means it may require several treatments to be fully effective. That said VitroGro is not usually just a single application either - so mybe we don't have much advantage there.
In the medium term it could be a serious threat to TIS not the least because they are trialing in the US although obviously it's not a human trial. It is quite likely that results from the TIS FDA trial could be as much as 3 years away so a lot can happen - hopefully the fact we have device claasification will help speed things up for TIS - but not sure whether the competition will simply be claiming all they are doing is using a novel method of delivery so new new drug testing is required.
In the long-term it's going to be battle for market share along with any other companies that put there hand up.
Once TIS recovers from it's current demise which I'm very confident it will I will be taking profits and watching future events unfold from the sidelines!
TIS Price at posting:
11.5¢ Sentiment: Hold Disclosure: Held
